KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$0.87.

  • Inovio Pharmaceuticals' EPS (Basic) rose 224.72% to -$0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.59, marking a year-over-year increase of 4205.82%. This contributed to the annual value of -$3.97 for FY2024, which is 3482.26% up from last year.
  • Per Inovio Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.87 for Q3 2025, which was up 224.72% from -$0.61 recorded in Q2 2025.
  • Inovio Pharmaceuticals' 5-year EPS (Basic) high stood at -$0.15 for Q3 2022, and its period low was -$16.5 during Q4 2021.
  • Its 5-year average for EPS (Basic) is -$2.3, with a median of -$0.87 in 2025.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' EPS (Basic) tumbled by 1131900.6% in 2021, and later surged by 9176.2% in 2023.
  • Inovio Pharmaceuticals' EPS (Basic) (Quarter) stood at -$16.5 in 2021, then increased by 20.55% to -$13.11 in 2022, then skyrocketed by 91.76% to -$1.08 in 2023, then surged by 33.47% to -$0.72 in 2024, then dropped by 21.07% to -$0.87 in 2025.
  • Its EPS (Basic) was -$0.87 in Q3 2025, compared to -$0.61 in Q2 2025 and -$0.51 in Q1 2025.